Boston Scientific Corporation
- Open
- 45.02
- Day high
- 45.25
- Day low
- 43.76
- Prev close
- 44.62
- Volume
- 13.9M
- Mkt cap
- $65.4B
- P/E (TTM)
- 18.3
- EPS (TTM)
- $2.40
- P/B
- 2.5
- P/S
- 3.2
- Yield
- —
- Per share
- —
- ▲Insiders net buying $554K over the last 3 months (4 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions mixed (13F)
Boston Scientific Corporation (BSX) is a Healthcare company listed on NYSE. The stock is down 58% over the past year. Over the trailing 3 months, insiders filed 4 open-market buys and 0 sales (SEC Form 4).
Boston Scientific Corporation (BSX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 17 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BSX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 22, 2026 | $0.79 | $0.80 | +1.5% | $5.2B | +0.6% |
| Feb 4, 2026 | $0.78 | $0.80 | +2.4% | $5.3B | +0.1% |
| Oct 22, 2025 | $0.71 | $0.75 | +5.0% | $5.1B | +1.9% |
| Jul 23, 2025 | $0.72 | $0.75 | +3.4% | $5.1B | +3.4% |
| Apr 23, 2025 | $0.67 | $0.75 | +11.4% | $4.7B | +2.0% |
| Feb 5, 2025 | $0.66 | $0.70 | +6.5% | $4.6B | +3.2% |
| Oct 23, 2024 | $0.59 | $0.63 | +7.1% | $4.2B | +4.2% |
| Jul 24, 2024 | $0.58 | $0.62 | +6.3% | $4.1B | +2.3% |
| Jan 31, 2024 | $0.51 | $0.55 | +7.8% | $3.7B | +3.7% |
| Oct 26, 2023 | $0.48 | $0.50 | +4.2% | $3.5B | +1.5% |
| Jul 27, 2023 | $0.49 | $0.53 | +8.2% | $3.6B | +2.8% |
| Feb 1, 2023 | $0.47 | $0.45 | -4.3% | $3.2B | -0.0% |
BSX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Monson Jonathanofficer: EVP and CFO | Option | 2,087 | — |
| Jul 2, 2026 | Monson Jonathanofficer: EVP and CFO | Tax | 1,010 | $43.06 |
| May 21, 2026 | Pegus Cheryldirector | Buy | 1,770 | $56.49 |
| May 21, 2026 | LUDWIG EDWARD Jdirector | Buy | 3,580 | $56.68 |
| May 21, 2026 | Habiger David Cdirector | Buy | 2,250 | $55.92 |
| May 21, 2026 | Habiger David Cdirector | Buy | 2,200 | $56.95 |
| May 11, 2026 | Zane Ellen Mdirector | Grant | 3,800 | — |
| May 11, 2026 | Morano Susan Edirector | Grant | 1,281 | — |
| May 11, 2026 | Smith Cathy Rdirector | Grant | 3,800 | — |
| May 11, 2026 | LUDWIG EDWARD Jdirector | Grant | 3,800 | — |
| May 11, 2026 | Weber Christophe Pierredirector | Grant | 2,660 | — |
| May 11, 2026 | Mega Jessica Ldirector | Grant | 3,800 | — |
| May 11, 2026 | Weber Christophe Pierredirector | Grant | 1,140 | — |
| May 11, 2026 | Pegus Cheryldirector | Grant | 1,281 | — |
| May 11, 2026 | Weber Christophe Pierredirector | Grant | 1,767 | — |
Source: BSX SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
See the full BSX insider & 13F page →Boston Scientific Corporation company profile
Overview
Boston Scientific Corporation (NYSE:BSX) is a leading global medical device company founded in 1979 and headquartered in Marlborough, Massachusetts. The company went public in 1992 and has since grown to become one of the world's largest medical technology companies, developing, manufacturing, and marketing medical devices used in various interventional medical specialties worldwide. Boston Scientific operates through three primary segments and has established itself as a major player in the medical device industry through both organic growth and strategic acquisitions.
Business
Boston Scientific operates in the medical device industry, which develops and manufactures sophisticated medical equipment used by healthcare professionals to diagnose, treat, and manage various medical conditions. The company's products are primarily used in interventional procedures - minimally invasive medical treatments that use specialized devices inserted through small incisions or natural body openings, rather than traditional open surgery. The company operates through three main business segments: MedSurg Segment (approximately 40% of revenue): This segment includes urology devices for treating urological and pelvic conditions, endoscopy products for gastrointestinal and pulmonary procedures, and neuromodulation systems. Key products include devices for kidney stone removal, bladder control systems, gastrointestinal stents, and spinal cord stimulators for chronic pain management. The neuromodulation products use electrical stimulation to treat conditions like chronic pain and movement disorders. Cardiovascular Segment (approximately 45% of revenue): This is Boston Scientific's largest segment, focusing on heart-related medical devices. It includes drug-eluting stents (tiny mesh tubes coated with medication that are placed in blocked coronary arteries), balloon catheters, imaging systems for heart procedures, and structural heart devices. The segment also includes the company's breakthrough WATCHMAN device, which is implanted in the heart to prevent stroke in patients with atrial fibrillation (irregular heartbeat). Rhythm and Neuro Segment (approximately 15% of revenue): This segment produces cardiac rhythm management devices including pacemakers, defibrillators, and electrophysiology products. Electrophysiology devices are used to diagnose and treat heart rhythm disorders through procedures that map the heart's electrical system and can destroy abnormal tissue causing irregular heartbeats. The segment's standout product is FARAPULSE, a revolutionary pulsed field ablation system that uses electrical pulses rather than heat or cold to treat atrial fibrillation.
Revenue model
Boston Scientific generates revenue primarily through product sales to hospitals, surgery centers, and healthcare providers worldwide. The company sells its medical devices directly to healthcare institutions and through distributors, with pricing typically negotiated through group purchasing organizations and health systems. The company's customers are primarily hospitals, ambulatory surgery centers, and specialty clinics that perform interventional procedures. Healthcare providers purchase these devices for use in patient treatments, with costs often reimbursed through insurance systems including Medicare, Medicaid, and private insurance plans. The reimbursement landscape significantly impacts demand, as procedures must be economically viable for healthcare providers. Revenue growth is driven by several factors: procedure volume increases as populations age and chronic diseases become more prevalent, market share gains through innovative products that offer better clinical outcomes, geographic expansion into emerging markets, and premium pricing for breakthrough technologies. The company's recent success with FARAPULSE exemplifies this model - the revolutionary technology commands premium pricing while rapidly gaining market share due to superior safety and efficacy profiles. Margin pressures come from various sources including healthcare cost containment efforts, competitive pricing pressure, regulatory compliance costs, and supply chain inflation. Volume-based procurement programs, particularly in markets like China, can significantly reduce pricing. However, margins benefit from manufacturing scale economies, product mix shifts toward higher-margin innovative devices, and operational efficiency improvements. The company's focus on faster-growing, higher-margin market segments has helped improve overall profitability, with recent margin expansion driven by strong performance in electrophysiology and structural heart products.
Risks & safety
Boston Scientific demonstrates a moderate margin of safety with strong operational performance but elevated valuation metrics. • Liquidity and Solvency: Current ratio of 1.45 indicates adequate short-term liquidity. Cash position of $725 million is relatively modest given the company's size, but strong free cash flow generation of $354 million quarterly provides financial flexibility. Debt-to-equity ratio of 0.53 represents manageable leverage levels. • Valuation Concerns: Price-to-earnings ratio of 55.3x and EV/EBITDA of 33.0x reflect premium valuations that embed high growth expectations. Price-to-book ratio of 6.7x indicates significant premium to tangible assets. • Growth Sustainability: Strong revenue growth of 22% operational and 18% organic growth in Q1 2025, driven by breakthrough products like FARAPULSE. However, maintaining this growth rate will be challenging as the company scales and competition intensifies. • Cash Generation: Positive free cash flow generation provides some downside protection, though current levels are modest relative to market capitalization.
Recent development
Boston Scientific has undergone significant strategic transformation over the past few years, shifting its portfolio toward faster-growing, higher-margin market segments. The most significant development has been the FARAPULSE revolution in electrophysiology, which launched commercially and achieved over $1 billion in revenue in 2024 while treating more than 200,000 patients globally. This pulsed field ablation technology represents a paradigm shift in treating atrial fibrillation, offering superior safety compared to traditional thermal methods. The company has pursued an aggressive acquisition strategy to strengthen its portfolio and expand into adjacent markets. Key acquisitions include Axonics (pelvic health), Silk Road Medical (neurovascular), and the pending acquisitions of Bolt Medical and SoniVie (ultrasound-based renal denervation). These transactions demonstrate Boston Scientific's commitment to building leadership positions in high-growth therapeutic areas. Geographic expansion has been another key focus, with strong performance in international markets including China, Japan, and Europe. The company has invested in local manufacturing capabilities and regulatory approvals to capture growth in emerging markets while navigating volume-based procurement pressures. Innovation pipeline development has accelerated across multiple business units. Beyond FARAPULSE, the company is advancing WATCHMAN technologies for stroke prevention, developing next-generation cardiac rhythm management systems including the Empower modular platform, and expanding its interventional oncology portfolio. Clinical trial investments have increased substantially to support label expansions and new product approvals, positioning the company for sustained growth beyond current breakthrough products.
BSX company profile · for informational purposes only — not investment advice.
Track BSX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free